87 related articles for article (PubMed ID: 23666667)
1. Guest editorial: efficacy of and resistance to molecularly targeted therapy for myeloid malignancies.
Kiyoi H
Int J Hematol; 2013 Jun; 97(6):681-2. PubMed ID: 23666667
[No Abstract] [Full Text] [Related]
2. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents.
Tonks A; Pearn L; Mills KI; Burnett AK; Darley RL
Leukemia; 2006 Oct; 20(10):1883-5. PubMed ID: 16932340
[No Abstract] [Full Text] [Related]
3. Molecular targets and the treatment of myeloid leukemia.
Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
[TBL] [Abstract][Full Text] [Related]
4. Incorporating novel treatment strategies into conventional therapy.
Estey EH
Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
[No Abstract] [Full Text] [Related]
5. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.
Eisele L; Klein-Hitpass L; Chatzimanolis N; Opalka B; Boes T; Seeber S; Moritz T; Flasshove M
Acta Haematol; 2007; 117(1):8-15. PubMed ID: 17095854
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of drug resistance in acute myeloid leukaemia.
McLornan DP; McMullin MF; Johnston P; Longley DB
Expert Opin Drug Metab Toxicol; 2007 Jun; 3(3):363-77. PubMed ID: 17539744
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
8. Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity.
Reikvam H; Nepstad I; Tamburini J
Expert Opin Investig Drugs; 2013 Nov; 22(11):1365-70. PubMed ID: 24099404
[TBL] [Abstract][Full Text] [Related]
9. CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells.
Prenkert M; Uggla B; Tidefelt U; Strid H
Anticancer Res; 2010 Oct; 30(10):4157-61. PubMed ID: 21036735
[TBL] [Abstract][Full Text] [Related]
10. Molecular characteristics therapy in AML.
Radich GP
Clin Adv Hematol Oncol; 2009 Jun; 7(6):11-4. PubMed ID: 19645131
[No Abstract] [Full Text] [Related]
11. Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
Lei H; Wang W; Wu Y
Leuk Lymphoma; 2018 Oct; 59(10):2297-2304. PubMed ID: 29198160
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy: overcoming drug resistance with clinical cancer genome.
Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
[No Abstract] [Full Text] [Related]
13. Philadelphia chromosome unmasked as a secondary genetic change in acute myeloid leukemia on imatinib treatment.
Yip SF; Wan TS; Liu HS; Wong ML; So CC; Chan LC
Leukemia; 2006 Nov; 20(11):2050-1. PubMed ID: 17024117
[No Abstract] [Full Text] [Related]
14. Clinical trials in adult AML.
Stock W
Clin Adv Hematol Oncol; 2009 Jun; 7(6):8-10. PubMed ID: 19645130
[No Abstract] [Full Text] [Related]
15. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.
Shojaei F; Wu X; Malik AK; Zhong C; Baldwin ME; Schanz S; Fuh G; Gerber HP; Ferrara N
Nat Biotechnol; 2007 Aug; 25(8):911-20. PubMed ID: 17664940
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
Morgan MA; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of multidrug resistance in AML: current insights.
Baer MR
Clin Adv Hematol Oncol; 2005 Dec; 3(12):910-2. PubMed ID: 16555430
[No Abstract] [Full Text] [Related]
18. [Treatment of leukemia in adults].
Gjemdal T
Tidsskr Nor Laegeforen; 1974 Jan; 94(3):164-7. PubMed ID: 4522749
[No Abstract] [Full Text] [Related]
19. Progress in the treatment of acute myeloid leukemia.
Ravandi F; Burnett AK; Agura ED; Kantarjian HM
Cancer; 2007 Nov; 110(9):1900-10. PubMed ID: 17786921
[TBL] [Abstract][Full Text] [Related]
20. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Lancet JE; List AF; Moscinski LC
Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
